Drug Trial Radar · NCT06749899
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
580
Planned (sponsor's estimate)
Start
May 4, 2025
Primary completion
Dec 1, 2028
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- Sun Yat-Sen University Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Qilu Pharmaceutical Co., Ltd.
- First posted
- Dec 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
Conditions
- Nasopharyngeal Cancinoma (NPC)
- Nasopharyngeal Cancer
Interventions
QL1706Drug
QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
GemcitabineDrug
Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
CisplatinDrug
Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Intensity-modulated radiotherapyRadiation
Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Failure-free survival (FFS) in intention-to-treat populationTime frame: 3 years
- Overall survival (OS) in intention-to-treat populationTime frame: 5 years
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Dongguan People's Hospital
Dongguan, Guangdong, China · Not yet recruiting
First People's Hospital of Foshan
Foshan, Guangdong, China · Not yet recruiting
Guangzhou Panyu Central Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Zhongshan People's Hospital
Zhongshan, Guangdong, China · Not yet recruiting
Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
Hubei Province Cancer Hosiptal
Wuhan, Hubei, China · Not yet recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The Eye and ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Fujian, Xiamen, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.